Osimertinib Shows Potential to Alter SOC in Advanced EGFR+ NSCLC
Osimertinib given after chemoradiation in patients with advanced non–small cell lung cancer harboring a EGFR mutation showed significant benefits.
Osimertinib (Tagrisso) given after definitive chemoradiotherapy led to significant and clinically meaningful improvement in progression-free survival (PFS) in patients with locally advanced, unresectable, stage III non–small cell lung cancer (NSCLC) harboring an EGFR mutation, according to data from the phase 3 LAURA trial (NCT03521154).1,2
Findings presented during a press briefing at the 2024 ASCO Annual Meeting demonstrated that treatment with osimertinib reduced the risk of progression or death by 84% compared with placebo (HR, 0.16; 95% CI, 0.10-0.24; P < .001). Patients treated with osimertinib (n = 143) experienced a median PFS of 39.1 months (95% CI, 31.5–not calculable) vs 5.6 months (95% CI, 3.7-7.4) for patients who received placebo (n = 73).1
The 12- and 24-month PFS rates in the osimertinib arm were 74% and 65%, respectively. Those respective rates were 22% and 13% in the placebo arm.
3D rendered medical illustration of male anatomy with lung cancer:© Sebastian Kaulitzki- stock.adobe.com
“Based on these results, osimertinib will become the new standard of care for patients with [EGFR-mutated], locally advanced NSCLC following definitive chemoradiation. EGFR mutation testing should be conducted for patients with stage III disease in order for patients to achieve optimal outcomes,” lead study author Suresh S. Ramalingam, MD, FACP, FASCO, executive director of Winship Cancer Institute of Emory University and associate vice president for cancer of Woodruff Health Sciences Center in Atlanta, Georgia, said in the press briefing.
For patients with unresectable stage III NSCLC, consolidation durvalumab (Imfinzi) is the standard of care after chemoradiotherapy for patients who do not experience disease progression. However, the benefit of durvalumab consolidation is unclear for patients who harbor EGFR mutations, based on a post-hoc analysis from phase 3 PACIFIC trial (NCT02125461), which did not show a significant PFS difference between durvalumab (n = 24) and placebo (n = 11) in patients with EGFR-mutated disease (HR, 0.91; 95% CI, 0.39-2.13).3
Notably, no targeted therapies are currently approved for patients with EGFR-mutated, unresectable, stage III NSCLC.1
LAURA was a double-blind, placebo-controlled trial that enrolled patients at least 18 years of age (or at least 20 years of age in Japan) with locally advanced, unresectable, stage III NSCLC harboring an EGFR exon 19 deletion or L858R mutation who did not experience disease progression following definitive chemoradiotherapy.1,4 Patients needed to have a WHO performance status of 0 or 1, and the maximum interval between the last dose of chemoradiotherapy and randomization was 6 weeks.1
Patients were randomly assigned 2:1 to receive 80 mg of oral osimertinib or placebo once per day. Treatment continued until blinded independent central review (BICR)–assessed disease progression per RECIST 1.1 criteria, unacceptable toxicity, or other discontinuation criteria were met.
Notably, patients in both arms were permitted to receive open-label osimertinib follow BICR-confirmed disease progression. Tumor assessments were conducted via chest CT/MRI and brain MRI at baseline, then once every 8 weeks until week 48, then once every 12 weeks thereafter until BICR-confirmed progression.
Stratification factors included method of chemoradiotherapy (concurrent vs sequential), disease stage (IIIA vs IIIB/C), and location (China vs not China).
BICR-assessed PFS per RECIST 1.1 criteria served as the trial’s primary end point. Secondary end points included overall survival (OS), central nervous system PFS, and safety.
OS data were immature at data cutoff; however, Ramalingam noted that a trend favoring osimertinib was observed, “[despite] a high proportion of patients crossing over from the control arm [81%].”
Additional data showed 22 patients in the osimertinib arm experienced new lesions compared with 68 patients in the placebo arm. Sites of new lesions included the brain (osimertinib, n = 8; placebo, n = 29), lung (n = 6; n = 29), liver (n = 3; n = 7), lymph nodes (n = 1; n = 7), bone (n = 1; n = 1), adrenal (n = 1; n = 0), peritoneum/omentum (n = 1; n = 0), pelvis (n = 1; n = 0), spleen (n = 0; n = 1), and other (n = 1; n = 0).
Regarding safety, Ramalingam said findings for osimertinib following chemoradiotherapy were consistent with the known safety profile of the EGFR inhibitor and manageable, noting that most adverse effects (AEs) were not serious, were grade 1/2, and did not lead to treatment discontinuation.
The most common any-grade AEs reported in at least 10% of patients included radiation pneumonitis (osimertinib, 48%; placebo, 38%), diarrhea (36%; 14%), rash (24%; 14%), COVID-19 (20%; 8%), paronychia (17%; 1%), cough (16%; 10%), decreased appetite (15%; 5%), dry skin (13%; 5%), pruritus (13%; 7%), stomatitis (12%; 3%), decreased white blood cell count (12%; 3%), pneumonia (11%; 8%), anemia (10%; 4%), and musculoskeletal chest pain (3%; 12%).
Grade 3 or higher AEs in the osimertinib arm included pneumonia (3%), radiation pneumonitis (2%), diarrhea (2%), COVID-19 (1%), decreased appetite (1%), dry skin (1%), decreased white blood cell count (1%), and anemia (1%).
“The LAURA trial is the first to define the role of EGFR-directed therapy in unresectable stage III disease. While the study did not compare osimertinib to the current standard-of-care immunotherapy, these data have major implications for both patients and oncologists and will change the standard of care for patients with EGFR mutations,” David R. Spigel, MD, chief scientific officer of Sarah Cannon Research Institute in Nashville, Tennessee, stated in a news release.2
